COMMUNIQUÉS West-GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results
27/02/2018
Roxadustat U.S. Phase 3 Program in CKD Anemia Enrollment Completion and Data Readout in 2018 Pamrevlumab Phase 2 IPF Study Achieves Statistically Significant Attenuation of Lung Fibrosis as Measured by Quantitative HRCT [...]
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results
27/02/2018
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today reported recent business progress and financial results for the fourth quarter and year ended [...]
K2M Group Holdings, Inc. to Participate in Four Investor Conferences in March
27/02/2018
LEESBURG, Va., Feb. 27, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (NASDAQ: KTWO ) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three- [...]
Humanigen Completes Exchange of Loan Obligations for Equity
27/02/2018
Company Transformation Continues, Focused on Making CAR-T Safer, Better, More Routine Lenzilumab Nears Start of Clinical Testing to Prevent Critical CAR-T-related Neurotoxicity BRISBANE, Calif., Feb. 27, 2018 (GLOBE [...]
Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTI
27/02/2018
- VABOMERE demonstrated a greater numerical overall success rate vs piperacillin-tazobactam - VABOMERE safety profile comparable to piperacillin-tazobactam NEW HAVEN, Conn., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Melinta [...]
IRIDEX to Present at the 30th Annual Roth Conference
27/02/2018
MOUNTAIN VIEW, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX ) today announced the Company plans to participate in the upcoming 30 th Annual Roth Conference in Orange County, CA. IRIDEX’s [...]
TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
27/02/2018
ZEJULA is the #1 PARP inhibitor for women with ovarian cancer in the U.S. 2017 ZEJULA ® net sales totaled $109 million during first nine months of commercial launch Focused clinical development program for niraparib in [...]
Wright Medical Group N.V. Reports 2017 Fourth Quarter and Full-Year Financial Results and Provides 2018 Annual Guidance
27/02/2018
Fourth Quarter 2017 Net Sales of $218 Million; Full-Year 2017 Net Sales of $745 Million Fourth Quarter 2017 Net Income From Continuing Operations of $27 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $ [...]
GenMark Diagnostics Reports Fourth Quarter and Full Year 2017 Results
27/02/2018
CARLSBAD, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK ), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the [...]
Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results
27/02/2018
Company gains alignment to proceed on Subpart H accelerated approval pathway for sparsentan in FSGS; Study start-up activities ongoing to initiate Phase 3 pivotal trial in second quarter of 2018 Clinical development of [...]
AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
27/02/2018
– On track to request pre-BLA meeting with FDA in Q2 2018 – – Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of 2018 – – Anticipates IND [...]
Teladoc Announces Full Year and Fourth Quarter 2017 Results
27/02/2018
2017 Revenue of $233.3 million, growth of 89%; 4Q 2017 Revenue of $77.1 million, growth of 106% Total Paid Membership of 23.2 million, growth of 33% 2017 Visits of 1,463,000, growth of 54%; 4Q 2017 Visits of 464,000, [...]
Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
27/02/2018
-- Plazomicin New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA); June 25, 2018 set as PDUFA action date -- -- Orally-administered antibacterial candidate C-Scape achieved positive top-line [...]
Atara Biotherapeutics Announces Proposed Offering of Common Stock
27/02/2018
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]
Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors
27/02/2018
– Patrick Machado, Co-founder and Former Chief Business and Financial Officer of Medivation, Brings Significant Experience in Building Value in the Prostate Cancer Space – WEST LAFAYETTE, Ind., Feb. 27, 2018 (GLOBE [...]
MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results
27/02/2018
Q4 and 2H 2017 Afrezza net revenue were $4.5 million (+238%) and $6.4 million (+240%) vs. 2016, respectively Q4 and 2H 2017 net cash used in operating activities were $30.0 million and $53.3 million, respectively Cash [...]
MacroGenics Provides Update on Corporate Progress and 2017 Financial Results
27/02/2018
ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
27/02/2018
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018, [...]
Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives to Change People’s Lives Living with Rare Diseases
27/02/2018
CRANBURY, N.J., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) is honoring Rare Disease Day this week with the launch of Healing Beyond Disease™, a global, Amicus employee-driven initiative [...]

Pages